Research programme: lantibiotics - Sentinella Pharmaceuticals

Drug Profile

Research programme: lantibiotics - Sentinella Pharmaceuticals

Alternative Names: Nai 107; NAI 112; Nai 112; NAI 802; NAI-107

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NAICONS
  • Developer Sentinella Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Cell wall inhibitors; TRPV cation channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain
  • No development reported Gram-positive infections

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for preclinical development in Gram-positive-infections in USA (IV, Injection)
  • 21 Mar 2016 Preclinical development for Gram-positive infections is ongoing in USA
  • 02 Dec 2015 Preclinical trials in Neuropathic pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top